QUEBEC CITY, Nov. 30 /CNW/ - Medicago Inc. (TSX-V: MDG) (the "Company"),
a developer and manufacturer of protein-based vaccines using a proprietary
transient expression system, today announced that it has been invited to
present at the World Health Organization's Third Meeting on Influenza Vaccines
that induce Broad Spectrum and Long-Lasting Immune Response. Dr. Louis Vezina,
Chief Scientist of Medicago will be presenting the Company's preclinical
results of a vaccine candidate for H5N1 Avian Influenza generated from
plant-made Virus-Like Particles ("VLP").
The meeting will be held in Geneva, Switzerland on December 3 and
December 4, 2007 and will be attended by leading scientists in the development
of influenza vaccines. The objective of the meeting will be to review new
technologies for the development of influenza vaccines, focusing on solutions
that induce a broad spectrum and long-lasting immune responses and that
provide cross-protection against different influenza viruses.
"World leading experts in vaccine development have been invited to this
WHO conference, providing us with an excellent opportunity to increase
awareness for the capabilities of our proprietary vaccine development and
manufacturing technologies," said Dr. Vezina. "We look forward to discussing
recent preclinical results from our lead VLP vaccine, which has demonstrated
high levels of potency against the lethal Indonesia strain of the H5N1 Avian
Influenza virus, and to presenting our plant-based technology, which
significantly increases vaccine manufacturing capacity."
A summary of the meeting and presentations will be published in the
coming months on the World Health Organization's website at www.who.int.
About Medicago Inc.
Medicago is committed to provide highly effective and affordable vaccines
based on proprietary Virus-Like Particle (VLP) and manufacturing technologies.
Medicago is developing VLP vaccines to protect against H5N1 pandemic
influenza, using a transient expression system which produces recombinant
vaccine antigens in the cells of non-transgenic plants. This technology has
potential to offer advantages of speed and cost over competitive technologies.
It could deliver a vaccine for testing in about a month after the
identification and reception of genetic sequences from a pandemic strain. This
production time frame has the potential to allow vaccination of the population
before the first wave of a pandemic strikes and to supply large volumes of
vaccine antigens to the world market.
Additional information about Medicago is available at www.medicago.com
Forward Looking Statements
This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation
to update these forward-looking statements.
The TSX Venture Exchange assumes no responsibility for the content or
accuracy of this press release
For further information:
For further information: Medicago Inc.: Andy Sheldon, President and CEO,
(418) 658-9393; The Equicom Group Inc.: Arianna Vanin, Investor Relations,
(514) 844-4680, email@example.com